JIR
ANAB icon

James Investment Research’s AnaptysBio ANAB Stock Holding History

James Investment Research’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10,257
Closed -$318K – 578
2022
Q4 		$318K Buy
10,257
+3,732
+57% +$105K 0.04% 217
2022
Q3 		$166K Hold
6,525
– – 0.02% 281
2022
Q2 		$132K Hold
6,525
– – 0.02% 287
2022
Q1 		$161K Buy
+6,525
New +$197K 0.02% 290

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

James Investment Research's ANAB Position: Q1 2023 in Review

James Investment Research sold out of AnaptysBio (ANAB) in Q1 2023, closing a stake of 10,257 shares — an estimated $318K sold.

James Investment Research first reported a position in ANAB in Q1 2022 and held it in 4 quarters. The position peaked at $318K in Q4 2022. 113 funds tracked by Wall St. Rank hold ANAB as of Q1 2023.

  • James Investment Research reported no remaining AnaptysBio position as of Q1 2023 after selling out during the quarter.
  • James Investment Research sold 10,257 AnaptysBio shares in Q1 2023, an estimated $318K.
  • James Investment Research first reported a position in AnaptysBio in Q1 2022 and held it in 4 quarters.
  • James Investment Research's AnaptysBio position peaked at $318K in Q4 2022.
  • 113 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2023.

Based on James Investment Research's 13F filing for Q1 2023, filed 26 Apr 2023.